{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:26:39Z","timestamp":1758961599548,"version":"3.41.2"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T00:00:00Z","timestamp":1554854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00258","type":"journal-article","created":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T04:31:03Z","timestamp":1554870663000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["A Novel Antibody-Toxin Conjugate to Treat Mantle Cell Lymphoma"],"prefix":"10.3389","volume":"9","author":[{"given":"Gulam M.","family":"Rather","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siang-Yo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoltan","family":"Szekely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph R.","family":"Bertino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"25983","DOI":"10.18632\/oncotarget.25414","article-title":"Activated matriptase as a target to treat breast cancer with a drug conjugate","volume":"9","author":"Rather","year":"2018","journal-title":"Oncotarget."},{"key":"B2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/107327481201900307","article-title":"Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches","volume":"19","author":"Shah","year":"2012","journal-title":"Cancer Control."},{"key":"B3","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ajh.23176","article-title":"Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management","volume":"87","author":"Vose","year":"2012","journal-title":"Am J Hematol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"iii83","DOI":"10.1093\/annonc\/mdu264","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Dreyling","year":"2014","journal-title":"Ann Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/annonc\/5.suppl_1.S71","article-title":"Cyclin D1 overexpression in non-Hodgkin's lymphoma with chromosome 11 bcl-1 rearrangement","volume":"5","author":"Williams","year":"1994","journal-title":"Ann Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/978-1-62703-357-2_14","article-title":"Molecular detection of t(11;14)(q13;q32) in mantle cell lymphoma","volume":"999","author":"Yin","year":"2013","journal-title":"Methods Mol Biol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1007\/s00018-006-6298-x","article-title":"Matriptase and its putative role in cancer","volume":"63","author":"Uhland","year":"2006","journal-title":"Cell Mol Life Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2119\/2006-00022.List","article-title":"Matriptase: potent proteolysis on the cell surface","volume":"12","author":"List","year":"2006","journal-title":"Mol Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10616-009-9205-0","article-title":"Involvement of the cytoplasmic juxtamembrane region of matriptase in its exclusive localization to the basolateral membrane domain of Madin-Darby canine kidney epithelial cells","volume":"59","author":"Murai","year":"2009","journal-title":"Cytotechnology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0002-9440(10)64081-3","article-title":"Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo","volume":"15","author":"Oberst","year":"2001","journal-title":"Am J Pathol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1023\/A:1020985632550","article-title":"Deregulated activation of matriptase in breast cancer cells","volume":"19","author":"Benaud","year":"2002","journal-title":"Clin Exp Metastasis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.ajpath.2013.06.024","article-title":"Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-Cell lymphomas","volume":"183","author":"Chou","year":"2013","journal-title":"Am J Pathol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"C406","DOI":"10.1152\/ajpcell.00403.2010","article-title":"Increased matriptase zymogen activation in inflammatory skin disorders","volume":"300","author":"Chen","year":"2011","journal-title":"Am J Physiol Cell Physiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1074\/jbc.M109.055640","article-title":"Matriptase activation, an early cellular response to acidosis","volume":"285","author":"Tseng","year":"2010","journal-title":"J Biol Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1475-2867-13-89","article-title":"Acidic extracellular microenvironment and cancer","volume":"13","author":"Kato","year":"2013","journal-title":"Cancer Cell Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"12070","DOI":"10.18632\/oncotarget.2514","article-title":"Acidosis promotes invasiveness of breast cancer cells through ROS-AKT-NF-\u03baB pathway","volume":"5","author":"Gupta","year":"2014","journal-title":"Oncotarget."},{"key":"B17","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/nrc1478","article-title":"Why do cancers have high aerobic glycolysis?","volume":"4","author":"Gatenby","year":"2004","journal-title":"Nat Rev Cancer."},{"key":"B18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/B978-0-12-397927-8.00004-X","article-title":"Targeting the metabolic microenvironment of tumors","volume":"65","author":"Bailey","year":"2012","journal-title":"Adv Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/path.4218","article-title":"Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite","volume":"203","author":"Choi","year":"2013","journal-title":"J Pathol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrc3298","article-title":"Evolutionary dynamics of carcinogenesis and why targeted therapy does not work","volume":"12","author":"Gillies","year":"2012","journal-title":"Nat Rev Cancer."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1021\/mp200292c","article-title":"Drug resistance and cellular adaptation to tumor acidic pH microenvironment","volume":"8","author":"Wojtkowiak","year":"2011","journal-title":"Mol Pharm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"18237","DOI":"10.1074\/jbc.274.26.18237","article-title":"Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk","volume":"274","author":"Lin","year":"1999","journal-title":"J Biol Chem."},{"key":"B23","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1158\/1078-0432.843.11.2","article-title":"In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate","volume":"11","author":"Sanderson","year":"2005","journal-title":"Clin Cancer Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/bcp.12988","article-title":"Brentuximab vedotin, an antibody\u2013drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment","volume":"82","author":"Zhao","year":"2016","journal-title":"Br J Clin Pharmacol."},{"key":"B25","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1182\/blood.V114.22.3442.3442","article-title":"Long term results of BL22 (CAT-3888) in multiply relapsed hairy cell leukemia","volume":"114","author":"Kreitman","year":"2009","journal-title":"Blood."},{"key":"B26","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1158\/1078-0432.CCR-08-1456","article-title":"CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22 -expressing hematological malignancies","volume":"15","author":"Alderson","year":"2009","journal-title":"Clin Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1158\/0008-5472.CAN-14-3297","article-title":"Androgen-induced TMPRSS2 activates matriptase and promotes extracellular matrix degradation, prostate cancer cell invasion, tumor growth, and metastasis","volume":"75","author":"Ko","year":"2015","journal-title":"Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s13577-014-0101-3","article-title":"Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis","volume":"28","author":"Mukai","year":"2015","journal-title":"Hum Cell"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1038\/onc.2013.41","article-title":"HAI-2 suppresses the invasive growth and metastasis of prostate cancer through regulation of matriptase","volume":"33","author":"Tsai","year":"2014","journal-title":"Oncogene"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00258\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T16:46:53Z","timestamp":1663260413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00258\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,10]]},"references-count":29,"alternative-id":["10.3389\/fonc.2019.00258"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00258","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2019,4,10]]},"article-number":"258"}}